Subscribe to our Email Alerts

VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial

In this video, Amplia CEO and MD, Dr John Lambert, explains what's to come in the Phase 2 clinical trial for our Focal Adhesion Kinase (FAK) inhibitor, AMP945, in first-line patients with advanced pancreatic cancer.